HTN Meds Tied to Lower Mortality After Pancreatic Cancer Diagnosis
The mortality risk was lower for patients exposed to ACE inhibitors in first 3 years after pancreatic cancer diagnosis.
The mortality risk was lower for patients exposed to ACE inhibitors in first 3 years after pancreatic cancer diagnosis.
Sotorasib exhibited antitumor activity in a phase 1/2 trial of pretreated patients with KRAS G12C-mutated, advanced pancreatic cancer.
A model using routine clinical information can predict pancreatic ductal adenocarcinoma after diagnosis of impaired fasting glucose.
In addition to improved overall survival, patients in the neoadjuvant arm had longer disease-free survival and locoregional failure-free intervals.
In the KRYSTAL-1 trial, adagrasib produced a 100% disease control rate in patients with gastrointestinal cancers.
The median survival was significantly longer in patients who received opioid prescriptions than in those who did not.
The median overall survival was 7.5 months in the eryaspase arm and 6.7 months in the chemotherapy-alone arm.
Patients with pancreatic ductal adenocarcinoma may have been spared the COVID-related delays in care seen for other cancers, according to researchers.
The improvement in response did not translate to a survival benefit.
Researchers identified 23 symptoms associated with pancreatic ductal adenocarcinoma.